Literature DB >> 33423181

Obstructive Sleep Apnea in Obese Patients: a UK Population Analysis.

S Erridge1, O Moussa2, C McIntyre2, A Hariri3, N Tolley3, B Kotecha4, S Purkayastha2.   

Abstract

BACKGROUND: Obstructive sleep apnea (OSA) is an increasingly common disorder associated with increased cardiovascular disease, mortality, reduced productivity, and an increased risk of road traffic accidents. A significant proportion of patients with OSA in the UK are undiagnosed. This study aims to identify risk factors for OSA in an obese cohort.
METHOD: A population-based study was conducted of obese patients (BMI ≥ 30 kg/m2) from the Clinical Practice Research Datalink (CPRD). A logistic regression model was used to calculate odds ratios (ORs) for developing OSA according to other clinicopathological characteristics. Multivariate analysis was conducted of individual factors that affect the propensity to develop OSA. Statistical significance was defined as p < 0.050.
RESULTS: From 276,600 obese patients identified during a data extraction of the CPRD in July 2017, the prevalence of OSA was 5.4%. The following risk factors were found to be independently associated with increased likelihood of OSA: male sex (OR = 3.273; p < 0.001), BMI class II (OR = 1.640; p < 0.001), BMI class III (OR = 3.768; p < 0.001), smoking (OR = 1.179; p < 0.001), COPD (OR = 1.722; p < 0.001), GERD (OR = 1.557; p < 0.001), hypothyroidism (OR = 1.311; p < 0.001), acromegaly (OR = 3.543; p < 0.001), and benzodiazepine use (OR = 1.492; p < 0.001). Bariatric surgery was associated with reduced risk of OSA amongst this obese population (OR = 0.260; p < 0.001).
CONCLUSIONS: In obese patients, there are numerous comorbidities that are associated with increased likelihood of OSA. These factors can help prompt clinicians to identify undiagnosed OSA. Bariatric surgery appears to be protective against developing OSA.

Entities:  

Keywords:  Obesity; Obstructive sleep apnea; Risk factors; Screening

Mesh:

Year:  2021        PMID: 33423181     DOI: 10.1007/s11695-020-05196-7

Source DB:  PubMed          Journal:  Obes Surg        ISSN: 0960-8923            Impact factor:   4.129


  4 in total

1.  Sleep apnea as an independent risk factor for all-cause mortality: the Busselton Health Study.

Authors:  Nathaniel S Marshall; Keith K H Wong; Peter Y Liu; Stewart R J Cullen; Matthew W Knuiman; Ronald R Grunstein
Journal:  Sleep       Date:  2008-08       Impact factor: 5.849

Review 2.  Health Care Savings: The Economic Value of Diagnostic and Therapeutic Care for Obstructive Sleep Apnea.

Authors:  Nathaniel F Watson
Journal:  J Clin Sleep Med       Date:  2016-08-15       Impact factor: 4.062

3.  Differences between men and women in the clinical presentation of patients diagnosed with obstructive sleep apnea syndrome.

Authors:  Marha R Shepertycky; Katsuhisa Banno; Meir H Kryger
Journal:  Sleep       Date:  2005-03       Impact factor: 5.849

Review 4.  Obstructive sleep apnea is a common disorder in the population-a review on the epidemiology of sleep apnea.

Authors:  Karl A Franklin; Eva Lindberg
Journal:  J Thorac Dis       Date:  2015-08       Impact factor: 2.895

  4 in total
  3 in total

1.  High-Fat Diet-Induced Mitochondrial Dysfunction Promotes Genioglossus Injury - A Potential Mechanism for Obstructive Sleep Apnea with Obesity.

Authors:  Qingqing Chen; Xinxin Han; Meihua Chen; Bingjiao Zhao; Bingjing Sun; Liangyan Sun; Weihua Zhang; Liming Yu; Yuehua Liu
Journal:  Nat Sci Sleep       Date:  2021-12-23

2.  Feasibility of THRIVE oxygenation and intra-operative lung-protective ventilation in morbidly obese patients undergoing neurosurgical procedures.

Authors:  Balaji Vaithialingam; Radhakrishnan Muthuchellappan
Journal:  Saudi J Anaesth       Date:  2022-06-20

3.  High prevalence of obstructive sleep apnea in pregnant women with class III obesity: a prospective cohort study.

Authors:  Emma C Johns; Elizabeth A Hill; Stevie Williams; AbdelKebir Sabil; Renata L Riha; Fiona C Denison; Rebecca M Reynolds
Journal:  J Clin Sleep Med       Date:  2022-02-01       Impact factor: 4.062

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.